Heterologous secondary infections are at increased risk of developing dengue hemorrhagic fever (DHF) because of antibody-dependent enhancement (ADE). IgG subclasses can fix and activate complement and bind to Fcɣ receptors. These factors may also play an important role in the development of ADE and thus in the pathogenesis of DHF. The aim of this study was to analyze the indices of anti-dengue IgG subclasses in adult patients with febrile and hemorrhagic dengue in the acute phase. In 2013, 129 patients with dengue fever (DF) and 57 with DHF in Veracruz, Mexico were recruited for this study and anti-dengue IgM and IgG determined by capture ELISA. Anti-dengue IgG subclasses were detected by indirect ELISA. Anti-dengue IgG2 and IgG3 subclasses were detected in patients with dengue. IgG1 increased significantly in the sera of patients with both primary and secondary infections and DHF, but was higher in patients with secondary infections. The IgG4 subclass index was significantly higher in the sera of patients with DHF than in that of those with DF, who were in the early and late acute phase of both primary and secondary infection. In conclusion, indices of subclasses IgG1 and IgG4 were higher in patients with DHF.
symptomatic reinfection with the same serotype, which indicates that immunological memory is very effective in secondary infections with a homologous serotype (2) . However, secondary symptomatic infection with a heterologous serotype of DENV is relatively common in endemic regions (4) . The risk of developing DHF in secondary infection with a heterologous serotype of DENV or when heterologous antibodies have been transferred from the mother may be attributable to ADE (5) , which enhances or facilitates increased viremia in the host (3, 5) . Sub-neutralizing antibodies form virusimmune IgG complexes that enhance DENV attachment by engaging Fc g receptors and infecting monocyte/ macrophages (6) . Nevertheless, ADE alone is not sufficient to explain the occurrence of DHF during primary infection (2) . Also, only a small fraction of secondary infections with a heterotypic serotype lead to DHF (7) . Thus, there may be additional mechanisms by which antibodies promote vascular damage during infection.
In vitro assays have shown that FcgRIA/g and FcgRIIA modulate neutralization of DENV in a subclass IgG-dependent manner (8) . The four IgG subclasses have different structures; this is reflected in differences in the interactions between the variable, antigen-binding Fab-fragments and the constant Fc fragment. These differences influence their ability to activate the classic complement pathway, as well as their affinity for Fc receptors (9) . These factors are important in the pathogenesis of DHF.
Large amounts of DEN-specific IgG1 have been found in pediatric patients with DHF and dengue shock syndrome in the acute phase (10) . IgG1 and IgG4 are reportedly correlated with the severity of the disease in pediatric patients (11) .
The amounts of circulating IgG subclasses in the acute and convalescent stages of dengue differ and may vary between children and adults. Therefore, the aim of this study was to analyze the indices of anti-Dengue IgG subclasses in adult patients with febrile and hemorrhagic dengue in the acute phase.
MATERIALS AND METHODS

Study design
Blood samples were collected from patients from August to October 2013 during an outbreak of dengue in Veracruz, Mexico, a region in which the disease is endemic. The participants were classified as having DHF (n ¼ 57) or DF (n ¼ 129), these being defined according to the criteria described by the WHO, 2009 (12) ; namely, DF: platelet count >100 Â 10 9 /L and DHF, platelet count 
Serum samples
Blood samples were collected in Vacutainer tubes without anticoagulant and the serum separated by centrifugation at 1.157 g for 15 min in a LMC-3000 Biosan centrifuge (Biosan, Riga, Latvia).
Hematological and biochemical markers
Platelets, hemoglobin, hematocrit, leukocytes, neutrophils, lymphocytes, and monocytes were determined using a Coulter LH 500 Hematology Analyzer (Beckman Coulter, Indianapolis, IN, USA). ALT and AST were determined by spectrophotometry using AST reagent No. 442665 and ALT reagent No. 442620 in a Beckman Coulter Synchron ALX-CX9 Clinical System (Beckman Coulter). Concentrations of total protein and albumin were determined by spectrophotometry using Spinreact kits No. 10011291 and 1001020 (Spinreact, St. Esteve de Bas, Girona, Spain), respectively, in a Multiskan MCC, (Thermofisher, Austin, TX, USA).
Serotype-specific detection of dengue viruses
Viral RNA was extracted from the participants' sera and assayed with a Qiamp Viral RNA mini kit (Qiagen Cat. No. 52906; Qiagen, Germantown, MD, USA). Subsequently, the viral genome for the four serotypes was identified by multiplex quantitative RT-qPCR. Primers comprising flavivirus and four fluorogenic TaqMan probes specific for each serotype of DENV in the NS5 region were used (13) . A superscript III Platinum enzyme One-Step qRT-PCR Kit (Cat. No. 1732088; Invitrogen, Thermofisher, Austin, TX, USA) was used.
The analyses were performed in a LightCycler 480 instrument (Roche, Indianapolis, IN, USA). The strains DENV-1 (Hawaii), DENV-2 (New Guinea), DENV-3 (H-87) and DENV-4 (H-241) were used as positive controls.
Anti-dengue IgM and IgG capture ELISA
IgM and IgG anti-dengue in the participants sera were determined using capture ELISA kits EIA-3470 and EIA-3471 (DRG Diagnostics, Springfield, NJ, USA).
Anti-dengue IgG subclasses EIA DENV-2 (New Guinea) was used to infect Vero cells. The infected cells were cultured in Dulbecco's Modified Eagle's medium supplemented with antibiotics and 1% FBS until a cytopathic effect was evident. Subsequently, the cells were harvested and centrifuged for 15 min at 4500 g, 4°C, to remove cells and cell debris, and the resultant virus-rich supernatant stored in PBS in aliquots at À70°C until use in IgG subclass capture enzyme immunoassay. The protein concentration of the DENV-2 antigen was determined with the Bradford assay as 10 mg/mL. An internal capture EIA system was developed to determine the anti-dengue IgG subclasses. The antigen was diluted with carbonate buffer solution (NaHCO 3 and Na 2 CO 3 1 M, pH 9.6) to a concentration of 10 mg/mL. A 96-well polyvinyl microplate was coated for 24 hr at 4°C with Vero cells-derived virus (see above). The microwells were then washed three times with washing buffer (0.5% [vol/vol] Tween 20 in PBS). The plate were blocked with 5% (wt/vol) skim milk in PBS for 1 hr at 37°C and serum samples diluted 1:100 in PBS supplemented with 2% (wt/vol) skim milk. The microwells were then washed again three times. One hundred microliters of diluted serum samples was then added to the microwells and incubated for 1 hr at 37°C. The microwells were then washed again three times. Antihuman mAbs IgG1, IgG2, IgG3 and IgG4 conjugated with HRP (ab99774, ab99779, ab99829 and ab99817; Abcam, San Francisco, CA, USA) diluted 1:2000 in PBS-skim milk were added to the wells for 1 hr at 37°C. The microwells were then washed again three times before they were developed with o-phenylenediamine dihydrochloride as the substrate. The reaction was stopped by adding 2 N H 2 SO 4 (100 mL/well) and the absorbance read at 492 nm.
Calculations and statistical analysis
Anti-dengue IgM-and IgG-positive and Ànegative samples were designated according to a cut-off control, which was provided by a fabricant. Analyses were performed in duplicate and the absorbance averaged to obtain the cut-off value. Samples were considered positive when the absorbance was higher than 10% of the cut-off value and negative when it was lower than 10% of the cut-off value. The anti-dengue IgM and IgG indices thus obtained were categorized as high or low using the tertile method.
The indices of the anti-dengue IgG subclasses were calculated by using the following formula: index ¼ (OD of sample À OD of blank)/(OD of blank), where OD is optical density.
Values are expressed as the mean AE SD for each study group. Statistical significance was assessed by the MannWhitney test and odds ratios were used to determine associations. GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA, USA) was used for statistical analysis. P values <0.05 were considered to denote significance.
RESULTS
Association between neutrophil, lymphocyte and monocyte counts and development of DHF Hematological findings in patients with DHF and DF are shown in Table 1 Transaminase activity in the sera of patients with DF and DHF AST and ALT concentrations were higher in patients with DHF (133 and 59.36 U/L, respectively) than in those with DF (56.29 and 42.55 U/L, respectively), and were associated with DHF (OR ¼ 33.68 and 2.6, respectively). These results are shown in Table 1 .
Identification of viral serotypes in patients with DF and DHF
The viral genome was identified in 54 samples (29%) from 186 patients in the acute phase (Table 2 ). Of 46 samples from patients with DF, three (6.5%) had DENV-1, 42 (91.3%) DENV-2 and one (2.2%) DENV-4; whereas the eight samples from patients with DHF were identified as having DENV-2.
IgM and IgG indices in patients with DF and DHF
Anti-dengue IgM was detected in 23.26% (30/129) of the sera of patients with clinical diagnoses of DF and in 63.16% (36/57) of those with DHF, all of whom were in the acute phase. According to WHO criteria (12) , dengue patients are classified as in early ( 4 DAOS) or late (5-8 DAOS) acute phase. Anti-dengue IgM was detected in 12.12% (12/99) of the sera of patients with DF and 46.67% (7/15) of those with DHF in the early acute phase. In contrast, anti-dengue IgM was detected in 60% (18/30) of the sera of patients with DF and 69.05% 
Classification of dengue patients as having primary or secondary infection according to serum IgM and IgG findings
Tertile analysis showed that the cut-offs for IgM and IgG in the DF group were 2.161 and 1.665, respectively; whereas for the DHF group they were 2.662 for IgM and 2.133 for IgG (Fig. 3) . The patients were classified into the following seven groups according to their immunoglobulin indices: Negative IgM/High IgG, Negative IgM/Low IgG, Low IgM/High IgG, Low IgM/Low IgG, High IgM/ Low IgG, High IgM/Negative IgG and Low IgG/Negative IgG. IgM/IgG ratios were also calculated to enable classification as primary or secondary infection according to the WHO criteria (12) . Dengue infection was defined as primary if the IgM/IgG OD ratio was greater than 1.2 (sera diluted 1:100) and secondary if the ratio was less than 1.2 (12) . The results are shown in Table 3 .
Patients with secondary infection were found to have either high or low IgG indices with negative IgM (76.74%, 99/129) and were unlikely to develop DHF; only 36.84% (21/57) of patients with this pattern developed DHF. However, 22.81% (13/57) of the patients who presented as having primary infection had high IgM with low or negative IgG and they tended to develop DHF, 8.53% (11/ 129) of patients with DF having this pattern.
In total, findings in 13.18% (n ¼ 17) and 29.82% (n ¼ 17) of the sera of DF and DHF patients, respectively, were classified as indicating primary infection, whereas 86.82% (n ¼ 112) and 70.18% (n ¼ 40) of the sera of patients with DF and DHF respectively, were classified as indicating secondary infection.
Anti-dengue IgG subclass indices
The subclass IgG1 increased significantly in the sera of patients with DHF (2.040 AE 1.087, n ¼ 55; P ¼ 0.0017), Figure 4 . The IgG1 index was higher in patients with DHF in the late acute phase (2.159 AE 1.122, n ¼ 40) than in those with DF in the early acute phase (P ¼ 0.0002, Fig. 5 ). IgG1 index was also higher in sera of patients with DHF and secondary infection (2.132 AE 1.040, n ¼ 40, P ¼ 0.006) (Fig. 6) .
Furthermore, an increase of IgG4 was observed in patients with DHF (1.137 AE 1.060, n ¼ 55; P < 0.0001) (Fig. 4) ; the IgG4 index was significantly higher in patients with DHF than in those with DF in both the acute phases of the disease. Anti-dengue IgG1 indices were higher in sera of patients with DHF in the late acute phase (2.159 AE 1.122, n ¼ 40) than in DF patients who were in the early acute phase (P ¼ 0.0002) (d). Anti-dengue IgG4 indices were significantly higher in the sera of patients with DHF (1.177 AE 1.048, n ¼ 15) than in those with DF who were in the early acute phase (0.3800 AE 0.3188, n ¼ 97) (P ¼ 0.0003) (a). Anti-dengue IgG4 indices were significantly higher in the sera of patients with DHF (1.122 AE 1.078, n ¼ 40) than in those with DF (0.4563 AE 0.2865, n ¼ 24) who were in the late acute phase (P ¼ 0.0001) (b). The sera of patients who were in the late acute phase (1.122 AE 1.078, n ¼ 40) had higher anti-dengue IgG4 indices than in those with DF (0.3800 AE 0.3188, n ¼ 97) who were in early acute phase (P < 0.0001) (c).
P < 0.0001) infection (Fig. 6) . IgG3 values were similar in DF and DHF. IgG2 was increased in patients with DHF; however, this was not statistically significant (Fig. 4) . Interestingly, the ratios of IgG1/IgG2 and IgG3/IgG4 were 6.7 and 5.0 in patients with DF with primary and secondary infection, respectively; whereas in those with DHF they were 2.1 and 2.5 for primary and secondary infection, respectively.
DISCUSSION
During an outbreak of dengue in Veracruz in 2013, blood samples were collected from patients with clinical diagnoses of DF (n ¼ 129) and DHF (n ¼ 57). The commonest symptoms were fever, rash, headache, myalgia, arthralgia, retro-orbital pain, nausea and mild hemorrhagic manifestations such as bleeding gums. Patients with DHF had low platelet counts (<100Â 10 9 / L) and leucopenia (with high percentages of lymphocytes and monocytes, but overall neutropenia).
High serum of transaminases concentrations (AST and ALT) were found in patients with DHF, AST concentrations being higher than ALT concentrations in most patients with dengue. These findings suggest that impaired liver function in patients with dengue infection results directly from DENV's tropism for liver cells (14, 15) .
In this study we detected mainly the serotype DENV-2, which circulates most commonly in Mexico (16) . Previous studies have reported an association between a new lineage of DENV-2 and severe dengue; genotype IV of DENV-2 has the potential to re-emerge and cause major epidemics (17) .
In this study we classified the acute phase into early and late phases for the purposes of analyzing possible changes in IgG and IgM anti-dengue as well as IgG subclasses. The acute phase was defined as one to eight DAOS, the early acute phase from one to four DAOS, and the late acute phase from five to eight DAOS, which is the critical phase for developing DHF according to the WHO criteria (12) .
With the aim of classifying patients as having primary or secondary dengue infection, we performed tertile analysis to enable categorization of anti-dengue IgM or IgG indices as high or low; the 67% percentile was the resultant cut-off point. Thus, values above this cut-off point were considered high and values below were considered low for both immunoglobulins.
Serological testing showed that 63.16% (36/57) of patients with DHF and 23.3% (30/129) of those with DF were positive for anti-dengue IgM. The IgM index increased significantly in the late acute phase in both DF and DHF; however, there were no significant differences between them. The levels of viremia may be affected by the presence of specific IgM, through complement fixation and/or promotion of phagocytosis (16, 18) .
We detected anti-dengue IgG in 93.8% (121/129) of the sera of patients with DF and in 96.49% (55/57) of those with DHF. The IgG index was significantly greater in patients with DHF in both early and late acute phase than in those with DF. However, it did not increase significantly over time in either group.
Interestingly, the 76.74% (99/129) of patients with secondary infection had either high or low IgG indices with negative IgM, but infrequently developed DHF: only 36.84% (21/57) of patients with this pattern developed DHF. However, 22.81% (13/57) of the patients with primary infection had high IgM with low or negative IgG and they tended to develop DHF: 8.53% (11/129) of patients with DF were found to have this pattern. This suggests that not only the IgG index, but also a high IgM index in primary infection could predict development of DHF. Anti-dengue IgM from patients with DHF/dengue shock syndrome reportedly cross- react with platelets, increasing platelet lysis (19) . Additionally, murine anti-nonstructural-1 protein antibodies reportedly cross-react with human platelets (20) . However, other epitopes of DENV antigens can induce IgM autoantibodies to recognize epitopes on the surface of platelets.
In contrast, IgG subclasses likely mediate development of DHF in patients with secondary infection by contributing to ADE. By interactions with the FcɣR, pre-existing heterotypic antibodies can increase the severity of the disease by facilitating infection of target cells with increased viremia and cytokine levels (21) . Mast cells express Fc receptors and can also be infected via ADE when non-neutralized antibody-DENV complexes are absorbed through endocytosis mediated by Fc receptors, which promotes degranulation, a process that has been linked to endothelial damage and vascular leakage (4, 22) . Moreover, it has been shown that monoclonal IgG anti-dengue envelope protein promotes binding of DENV-2 to human platelets via both Fc and non-Fc receptors (23) . Also, DENV neutralization by IgG1, IgG3 and IgG4 mAbs is reportedly enhanced in high-affinity FcgRIA transfectants and diminished in low-affinity FcgRIIA transfectants, whereas neutralization by IgG2 mAbs is diminished equally. IgG3 mAbs exhibit the strongest neutralizing activity and IgG2 the weakest in FcgRnegative Vero cells. DENV neutralization is modulated by the Fc region in an IgG subclass manner, likely through effects on virion and FcgR binding. Thus, the IgG subclass profile generated by DENV infection or vaccination may independently influence the magnitude of the neutralizing response (24) .
We found that anti-dengue IgG1 increased significantly in the sera of patients with DHF and this this increase was greater in patients with secondary infection. IgG1 is the most abundant subclass and can efficiently trigger the classical route of complement and interact efficiently with most FCɣR (25) .
Also, anti-dengue IgG2 increased in DHF patients, but not to a statistically significant degree. IgG2 triggers the classical route of complement much less efficiently or only under certain conditions, this being attributable in large part to reduced binding of C1q (26) .
We detected Anti-dengue IgG3 in both DHF and DF, however, the values did not differ significantly between these groups. IgG3 is particularly effective in activating the classical route of complement and interacts efficiently with most FCɣR. Being a potent proinflammatory antibody, its shorter half-life may function to limit the potential for excessive inflammatory response (25) .
We found that anti-dengue IgG4 increases significantly in the sera of patients with DHF in the early and late acute phase; this increase was higher in DHF patients with secondary infection. IgG4 causes less complement activation by forming small immune complexes, probably because of their monovalency, and in this way can even reduce complement activation by IgG1 antibodies (27) . IgG4 only binds to FCɣRI (25) . The Th2 response, which controls B-cell class switching to IgG4, requires IL-4 or IL-13 cytokines. However, in a mediated Th2 response, IL-10 production in the presence of IL-4 drives class switching to IgG4 (28) . IL-10 is found in patients with dengue and is in higher concentrations in those with DHF, correlating with pleural effusion indices and decreases in platelet counts (29, 30) . This occurs most frequently in patients with secondary infections (31) . IL-4 is significantly increased in patients with severe clinical manifestations of dengue (32) . Therefore both cytokines may lead class switching to IgG4 in DENV infections.
Values for total IgG and its subclasses follow a typical pattern during childhood. Because IgG subclasses are transferred via the placenta, the IgG present at birth is mainly of maternal origin, and in different concentrations than in adults. The amounts of IgG subclasses are not normally distributed in different populations (9) . However, our findings correlate with those of a study performed in pediatric patients with DHF in the acute phase, in which high concentrations of DEN-specific IgG1 were found (10). Another study of pediatric patients with DHF found that anti-dengue IgG1 and IgG4 were the predominant subclasses (11); our findings are consistent with these results.
In conclusion, we identified DENV-2 in patients with high concentrations of IgG who did not develop DHF. Hence, both high concentrations of IgM and IgG antibodies are important for developing DHF. We also detected the subclasses IgG2 and IgG3 in patients with dengue. The indices of subclasses IgG1 and IgG4 were higher in patients with DHF.
